UY39590A - Procedimiento para preparar 4-{4-[({[4-cloro-3- (trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}n- metilpiridin-2-carboxamida, monohidrato y composiciones que lo comprenden - Google Patents
Procedimiento para preparar 4-{4-[({[4-cloro-3- (trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}n- metilpiridin-2-carboxamida, monohidrato y composiciones que lo comprendenInfo
- Publication number
- UY39590A UY39590A UY0001039590A UY39590A UY39590A UY 39590 A UY39590 A UY 39590A UY 0001039590 A UY0001039590 A UY 0001039590A UY 39590 A UY39590 A UY 39590A UY 39590 A UY39590 A UY 39590A
- Authority
- UY
- Uruguay
- Prior art keywords
- amino
- methylpyridine
- carboxamide
- monohydrate
- carbonyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Abstract
La presente invención se refiere a un procedimiento para preparar 4-{4-[({[4- cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-/\/-metilpiridin- 2-carboxamida, sus sales y monohidrato.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10004022 | 2010-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39590A true UY39590A (es) | 2022-01-31 |
Family
ID=44070712
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033290A UY33290A (es) | 2010-04-15 | 2011-03-24 | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}n-metilpiridin-2-carboxamida, sus sales y monohidrato |
UY0001039590A UY39590A (es) | 2010-04-15 | 2021-12-23 | Procedimiento para preparar 4-{4-[({[4-cloro-3- (trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}n- metilpiridin-2-carboxamida, monohidrato y composiciones que lo comprenden |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001033290A UY33290A (es) | 2010-04-15 | 2011-03-24 | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}n-metilpiridin-2-carboxamida, sus sales y monohidrato |
Country Status (39)
Country | Link |
---|---|
US (5) | US8748622B2 (es) |
EP (1) | EP2558448B1 (es) |
JP (1) | JP5934182B2 (es) |
KR (2) | KR101800041B1 (es) |
CN (2) | CN102947271B (es) |
AR (2) | AR081060A1 (es) |
AU (1) | AU2011240113B2 (es) |
BR (1) | BR112012026117B1 (es) |
CA (1) | CA2796238C (es) |
CL (1) | CL2012002840A1 (es) |
CO (1) | CO6630136A2 (es) |
CR (1) | CR20120526A (es) |
CU (2) | CU24123B1 (es) |
DK (1) | DK2558448T3 (es) |
DO (2) | DOP2012000268A (es) |
EC (1) | ECSP12012234A (es) |
ES (1) | ES2542610T3 (es) |
GT (1) | GT201200280A (es) |
HK (1) | HK1200831A1 (es) |
HR (1) | HRP20150885T1 (es) |
HU (1) | HUE026821T2 (es) |
IL (2) | IL222348B (es) |
JO (1) | JO3158B1 (es) |
MA (1) | MA34156B1 (es) |
MX (1) | MX2012011734A (es) |
MY (2) | MY177066A (es) |
NZ (1) | NZ602997A (es) |
PE (2) | PE20160838A1 (es) |
PL (1) | PL2558448T3 (es) |
PT (1) | PT2558448E (es) |
RS (1) | RS54219B1 (es) |
RU (1) | RU2581585C2 (es) |
SG (2) | SG10201501221UA (es) |
SI (1) | SI2558448T1 (es) |
TN (1) | TN2012000492A1 (es) |
TW (2) | TWI539951B (es) |
UA (1) | UA110613C2 (es) |
UY (2) | UY33290A (es) |
WO (1) | WO2011128261A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1797038B1 (en) * | 2004-09-29 | 2012-06-13 | Bayer Pharma Aktiengesellschaft | Thermodynamically stable form of bay 43-9006 tosylate |
CA2601955C (en) | 2005-03-07 | 2012-07-10 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
AR092439A1 (es) * | 2012-09-06 | 2015-04-22 | Bayer Healthcare Llc | Composicion farmaceutica recubierta que contiene regorafenib |
DK2900269T3 (en) | 2012-09-25 | 2018-10-01 | Bayer Pharma AG | COMBINATION OF REGORAFENIB AND ACETYLSALICYLIC ACID FOR TREATMENT OF COLORECTAL CANCER. |
CN104250227A (zh) * | 2013-06-29 | 2014-12-31 | 广东东阳光药业有限公司 | 瑞戈非尼新晶型及其制备方法 |
IN2013CH04511A (es) | 2013-10-04 | 2015-04-10 | Hetero Research Foundation | |
CN105218439B (zh) * | 2014-06-06 | 2018-11-20 | 连云港润众制药有限公司 | 一种瑞格非尼的晶体及其制备方法 |
US9790185B2 (en) | 2014-07-09 | 2017-10-17 | Shilpa Medicare Limited | Process for the preparation of regorafenib and its crystalline forms |
CN104557689B (zh) * | 2015-01-26 | 2016-06-29 | 重庆两江药物研发中心有限公司 | 制备4-[4-({[4-氯-3-(三氟甲基)苯基]氨基甲酰}氨基)-3-氟苯氧基]-n-甲基吡啶-2-甲酰胺及其一水合物的方法 |
CN104592105B (zh) * | 2015-02-10 | 2017-01-18 | 杭州朱养心药业有限公司 | 瑞戈非尼及其制法 |
CN105330600B (zh) * | 2015-11-30 | 2018-05-22 | 山东罗欣药业集团股份有限公司 | 一种瑞戈菲尼的制备方法 |
WO2017125941A1 (en) * | 2016-01-18 | 2017-07-27 | Natco Pharma Ltd | An improved process for the preparation of regorafenib |
CN107118153A (zh) * | 2016-02-25 | 2017-09-01 | 石药集团中奇制药技术(石家庄)有限公司 | 一种瑞戈非尼一水合物晶型及其制备方法 |
CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
CA3065125A1 (en) | 2017-06-02 | 2018-12-06 | Bayer Aktiengesellschaft | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
CN109438336B (zh) * | 2018-11-27 | 2019-11-22 | 广东安诺药业股份有限公司 | 一种瑞戈非尼水合物的制备方法 |
CN109438337B (zh) * | 2018-11-27 | 2019-08-09 | 广东安诺药业股份有限公司 | 一种瑞戈非尼中间体的制备工艺 |
EP3861989A1 (en) | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
WO2021160708A1 (en) | 2020-02-14 | 2021-08-19 | Bayer Aktiengesellschaft | Combination of regorafenib and msln-ttc for treating cancer |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
US20080269265A1 (en) | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
WO2000041698A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
DE60216139T3 (de) | 2001-12-03 | 2018-11-15 | Bayer Healthcare Llc | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen |
US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
WO2003068746A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
DE602004007382T2 (de) | 2003-05-20 | 2008-04-17 | Bayer Pharmaceuticals Corp., West Haven | Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten |
DE602004010407T2 (de) | 2003-07-23 | 2008-10-16 | Bayer Pharmaceuticals Corp., West Haven | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden |
JP2007535565A (ja) | 2004-04-30 | 2007-12-06 | バイエル ファーマシューティカルス コーポレーション | 癌の治療に有用な置換ピラゾリル尿素誘導体 |
DE602005007048D1 (de) | 2004-08-27 | 2008-07-03 | Bayer Pharmaceuticals Corp | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
UA90691C2 (en) | 2004-09-29 | 2010-05-25 | Баер Шеринг Фарма Акциенгезельшафт | Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide |
EP1797038B1 (en) | 2004-09-29 | 2012-06-13 | Bayer Pharma Aktiengesellschaft | Thermodynamically stable form of bay 43-9006 tosylate |
CA2601955C (en) | 2005-03-07 | 2012-07-10 | Bayer Healthcare Ag | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer |
JP2009513706A (ja) | 2005-10-31 | 2009-04-02 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | ソラフェニブを用いた癌の治療 |
US20100144749A1 (en) | 2005-11-14 | 2010-06-10 | Scott Wilhelm | Treatment of cancers with acquired resistance to kit inhibitors |
AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
WO2008055629A1 (en) * | 2006-11-09 | 2008-05-15 | Bayer Schering Pharma Aktiengesellschaft | Polymorph iii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
CA2669158A1 (en) * | 2006-11-14 | 2008-05-22 | Bayer Schering Pharma Aktiengesellschaft | Polymorph ii of 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide |
WO2008079968A1 (en) | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer |
EP2114403A2 (en) | 2007-01-19 | 2009-11-11 | Bayer Healthcare, LLC | Treatment of cancers having resistance to chemotherapeutic agents |
US8680124B2 (en) | 2007-01-19 | 2014-03-25 | Bayer Healthcare Llc | Treatment of cancers with acquired resistance to kit inhibitors |
EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
US20110257035A1 (en) | 2008-10-21 | 2011-10-20 | Bayer Healthcare Llc | Identification of signature genes associated with hepatocellular carcinoma |
BRPI1010979A2 (pt) | 2009-05-15 | 2018-03-06 | Novartis Ag | "combinação de um inibidor de fosfoinositídeo 3- quinase e de uma composto antidiabético" |
AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
JP2013531067A (ja) | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
PE20140165A1 (es) | 2010-10-01 | 2014-02-26 | Bayer Ip Gmbh | Combinaciones que contienen n-(2-arilamino)arilsulfonamida |
AU2012277905A1 (en) | 2011-06-28 | 2014-01-16 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing regorafenib |
US20140235678A1 (en) | 2011-06-28 | 2014-08-21 | Bayer Healthcare Llc | Topical Ophthalmological Pharmaceutical Composition containing Sorafenib |
US8841500B2 (en) | 2011-11-08 | 2014-09-23 | Chevron U.S.A. Inc. | Preparation of alkyl aromatic compounds |
JP2014032346A (ja) | 2012-08-06 | 2014-02-20 | Japan Display Inc | 液晶表示パネル |
AR092439A1 (es) | 2012-09-06 | 2015-04-22 | Bayer Healthcare Llc | Composicion farmaceutica recubierta que contiene regorafenib |
-
2011
- 2011-03-23 AR ARP110100982A patent/AR081060A1/es not_active Application Discontinuation
- 2011-03-24 UY UY0001033290A patent/UY33290A/es active IP Right Grant
- 2011-04-08 DK DK11712881.9T patent/DK2558448T3/en active
- 2011-04-08 CA CA2796238A patent/CA2796238C/en active Active
- 2011-04-08 MY MYPI2016001879A patent/MY177066A/en unknown
- 2011-04-08 US US13/640,959 patent/US8748622B2/en active Active
- 2011-04-08 PL PL11712881T patent/PL2558448T3/pl unknown
- 2011-04-08 MY MYPI2012004548A patent/MY162359A/en unknown
- 2011-04-08 PE PE2016000780A patent/PE20160838A1/es unknown
- 2011-04-08 RU RU2012148386/04A patent/RU2581585C2/ru active
- 2011-04-08 JP JP2013504206A patent/JP5934182B2/ja active Active
- 2011-04-08 MA MA35304A patent/MA34156B1/fr unknown
- 2011-04-08 CU CU20120147A patent/CU24123B1/es active IP Right Grant
- 2011-04-08 HU HUE11712881A patent/HUE026821T2/en unknown
- 2011-04-08 ES ES11712881.9T patent/ES2542610T3/es active Active
- 2011-04-08 SI SI201130559T patent/SI2558448T1/sl unknown
- 2011-04-08 SG SG10201501221UA patent/SG10201501221UA/en unknown
- 2011-04-08 RS RS20150528A patent/RS54219B1/en unknown
- 2011-04-08 AU AU2011240113A patent/AU2011240113B2/en active Active
- 2011-04-08 BR BR112012026117-7A patent/BR112012026117B1/pt active IP Right Grant
- 2011-04-08 PT PT117128819T patent/PT2558448E/pt unknown
- 2011-04-08 KR KR1020127026728A patent/KR101800041B1/ko active IP Right Grant
- 2011-04-08 KR KR1020177032906A patent/KR20170129276A/ko not_active Application Discontinuation
- 2011-04-08 MX MX2012011734A patent/MX2012011734A/es active IP Right Grant
- 2011-04-08 SG SG2012069852A patent/SG184172A1/en unknown
- 2011-04-08 PE PE2012002008A patent/PE20130181A1/es active IP Right Grant
- 2011-04-08 CN CN201180019150.1A patent/CN102947271B/zh active Active
- 2011-04-08 NZ NZ602997A patent/NZ602997A/en unknown
- 2011-04-08 WO PCT/EP2011/055508 patent/WO2011128261A1/en active Application Filing
- 2011-04-08 EP EP20110712881 patent/EP2558448B1/en active Active
- 2011-04-08 CN CN201410248545.4A patent/CN103980191A/zh active Pending
- 2011-04-13 JO JOP/2011/0125A patent/JO3158B1/ar active
- 2011-04-14 TW TW103141317A patent/TWI539951B/zh active
- 2011-04-14 TW TW100112905A patent/TWI475992B/zh active
- 2011-08-04 UA UAA201212983A patent/UA110613C2/uk unknown
-
2012
- 2012-10-08 EC ECSP12012234 patent/ECSP12012234A/es unknown
- 2012-10-10 CL CL2012002840A patent/CL2012002840A1/es unknown
- 2012-10-11 GT GT201200280A patent/GT201200280A/es unknown
- 2012-10-11 IL IL222348A patent/IL222348B/en active IP Right Grant
- 2012-10-12 TN TNP2012000492A patent/TN2012000492A1/en unknown
- 2012-10-12 CO CO12180992A patent/CO6630136A2/es not_active Application Discontinuation
- 2012-10-12 DO DO2012000268A patent/DOP2012000268A/es unknown
- 2012-10-16 CR CR20120526A patent/CR20120526A/es unknown
-
2014
- 2014-04-15 US US14/252,850 patent/US9458107B2/en active Active
- 2014-05-26 CU CU2014000060A patent/CU20140060A7/es unknown
-
2015
- 2015-02-10 HK HK15101433.6A patent/HK1200831A1/xx unknown
- 2015-08-19 HR HRP20150885TT patent/HRP20150885T1/hr unknown
-
2016
- 2016-09-08 US US15/259,576 patent/US20170057918A1/en not_active Abandoned
- 2016-10-20 DO DO2016000285A patent/DOP2016000285A/es unknown
-
2017
- 2017-06-22 IL IL253119A patent/IL253119B/en active IP Right Grant
- 2017-08-03 US US15/668,178 patent/US20170334857A1/en not_active Abandoned
-
2019
- 2019-01-09 US US16/243,284 patent/US10822305B2/en active Active
- 2019-09-13 AR ARP190102596A patent/AR116395A2/es unknown
-
2021
- 2021-12-23 UY UY0001039590A patent/UY39590A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39590A (es) | Procedimiento para preparar 4-{4-[({[4-cloro-3- (trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}n- metilpiridin-2-carboxamida, monohidrato y composiciones que lo comprenden | |
CY1125155T1 (el) | Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης | |
ECSP11011391A (es) | Métodos y productos intermedios para preparar agentes farmacéuticos | |
UY34161A (es) | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida, sus usos, y composiciones que la contienen | |
UY34559A (es) | Inhibidores de bromodominios | |
UY34365A (es) | Compuestos heterociclicos | |
CR20150061A (es) | Compuesto de pirazolopirimidinas | |
UY34416A (es) | ?sales de herbicidas de ácido carboxílico? | |
EA201590788A1 (ru) | Аминные соли лахинимода | |
UY34442A (es) | 2-tiopirimidinonas. | |
UA111333C2 (uk) | Спосіб одержання l-аргінінової солі периндроприлу | |
CO6650346A2 (es) | Composiciones de tetraciclina | |
UY4148Q (es) | Golosina para mascota | |
UY34038A (es) | Esteres aromaticos para composiciones agroquimicas. | |
BR112012026157A2 (pt) | processo para preparar ditiina-tetracarboximidas. | |
EA201200123A1 (ru) | Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
UY34032A (es) | Nuevos inhibidores de quinasa | |
BR112012026411A2 (pt) | processo para preparar ditiina-tetracarboxi-diiminas | |
DK3044214T3 (da) | Peptidylnitrilforbindelser som dipeptidylpeptidase-I-inhibitorer | |
BR112012029626A2 (pt) | processo para preparar ditianona-tetracarboxi-dimidas | |
UA111329C2 (uk) | Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою | |
UY34244A (es) | Compuesto heterocíclico que contiene nitrógeno | |
UA118008C2 (uk) | Спосіб синтезу (2е)-3-(3,4-диметоксифеніл)проп-2-еннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою | |
BR112013009176A2 (pt) | processo para a síntese de álcoois quirais propargílicos. | |
EA201391421A1 (ru) | Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана |